Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
Fortune Minerals Reports Successful NICO Project Bismuth Test Work Results for the Planned Alberta Refinery
Brunswick Exploration Announces Brokered Private Placement for Gross Proceeds of up to C$2.5 Million, with a Lead Order from a Strategic Investor